As per our research report, the size of the European enteral feeding formulas market has been forecasted at USD 1.51 billion in 2022 and is estimated to be growing at a CAGR of 7.6%, to worth USD 2.17 billion by 2027. Raising public awareness of illnesses and concerns about changing lifestyles and proper visits and medicine from physicians are driving the growth of the Europe Enteral Feeding Formulas Devices Market. In addition, the rising frequency of chronic illnesses and disorders, quickly growing senior population, rising healthcare spending, rising prevalence of preterm births, and increasing demand for home care drive the expansion of the European enteral feeding formulas market.
A surge in patients suffering from cardiovascular illnesses, cancer, and diabetes, the leading causes of mortality, has fuelled the enteral feeding formula industry. According to the WHO, cardiovascular diseases claimed the lives of 17.9 million people. In addition, as the quality of the food delivered by tube feeding has improved, demand for enteral feeding has increased significantly; as the elderly population grows, the rate of preterm deliveries rises, and the need for home care rises, all of these factors contribute to market expansion. Furthermore, some persons cannot take their meals orally, increasing tube feeding.
However, factors such as enteral nutrition problems, patient safety concerns, and the likelihood of feeding and medication mistakes are projected to limit the growth of the enteral feeding formulas market to some extent in the European region. For example, in enteral operations, several different formulas are utilized for feeding, and supplying one formula to someone who isn't a good fit might have detrimental implications. In addition, specific proteins and fatty acids cause allergic reactions in some individuals, necessitating the usage of disease-specific formulations. As a result, the market's expansion is limited by the incorrect formula selection. This is the market's most significant obstacle.
This research report on the European enteral feeding formulas market has been segmented and sub-segmented into the following categories:
By End User:
Geographically, the European enteral feeding formulas market was the second-largest regional market in the global market in 2020. The European Enteral Feeding Market is expected to be driven by increased rates of chronic illnesses and disorders, rising healthcare spending, rising rates of premature deliveries, and rising demand for home care. The enteral feeding formulae market is projected to be constrained by complications associated with enteral nutrition, patient safety issues, and the likelihood of feeding and medication mistakes. However, due to the development of serval technologically improved enteral feeding formula and an increase in the region's senior population, Europe is predicted to expand at the second-fastest rate from 2022 to 2027.
During the forecast period, the German enteral feeding formulas market is predicted to dominate the European Market. This is due to the rise in chronic disease cases. At the same time, increased awareness of enteral clinical nutrition's favorable function in disease treatment and prevention and enhanced, consistent, high-quality clinical data are projected to drive market growth.
The United Kingdom has a considerable market share in Europe Enteral Feeding Formulas Devices following Germany. The growing importance of the homecare market is good news for enteral feed producers. There has been a movement from extended hospital care to therapy at home due to continuing financial constraints in the hospital sector. In addition, patients are increasingly adopting enteral nutrition products at home, thanks to rising awareness of the necessity of therapeutic nutrition.
KEY MARKET PLAYERS:
Companies playing a leading role in the European enteral feeding formulas market profiled in this report are Abbott Laboratories (U.S.), Nestlé S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi AG (Germany), Mead Johnson Nutrition Company (U.S.), B. Braun Melsungen AG (Germany), Hormel Foods, LLC (U.S.), Victus Inc. (U.S.), Meiji Holdings Co., Ltd. (Japan), and Global Health Product Inc. (U.S.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com